Anthony King
I am a freelance science journalist based in Dublin, Ireland. I cover a variety of topics in chemical and biological sciences, as well as science policy, health and innovation.
My articles have appeared in Nature, Science, Cell, Chemistry World, New Scientist, the Irish Times, New York Times, EMBO Reports, Chemistry & Industry and more.
I enjoy writing on a wide breadth of subjects, from antibiotics to petrochemicals, bumblebees to asteroid composition, palaeontology to brain development. Previously I worked for a publishing company as a science editor.
My primary degree in science is from Trinity College Dublin and I hold a Master’s degree in science communications from Dublin City University.
FeatureThe problem of particulate air pollution
Small particles in the air can find their way into the brains of growing children, with seriously unpleasant consequences. Anthony King reports
NewsZero-emissions economy is both feasible and affordable for the UK
Committee on Climate Change backs low carbon target for 2050
ResearchNeonicotinoid exposure could be harming mammals
Deer study suggests the toxic effects of these pesticides may not be limited to insects
NewsBrexit delay welcomed by leading UK chemists
Scientists are pleased that a no-deal Brexit has been avoided, but uncertainty remains
ResearchGreen solvent recovers in-demand metals from batteries
Multiple cathode chemistries tackled by one system
ResearchAir on board diesel trains is five times worse than beside a busy street
Ultrafine particles and soot linked to lung cancer are massively elevated in carriages pulled by diesel engines
NewsLeading geneticists call for worldwide moratorium on creation of gene-edited children
Five-year pause would give nations breathing space following the birth of the first genetically-modified children in November
BusinessPower-hungry Tesla picks up supercapacitor maker
Maxwell Technologies deal highlights potential for supercapacitors in electric vehicles and beyond
NewsGenome sequencing for healthy dismissed as waste of time for UK project
Personalised medicine plan unlikely to deliver any benefits for the wider population
NewsWhy cadmium is a problem for chocoholics
The EU has set new limits on the heavy metal in your food
FeatureCan we live forever?
We are now living longer than ever before, but not always in perfect health. Anthony King talks to the researchers working to extend our healthspan
NewsRogue Chinese scientist to be punished for creation of first gene-edited humans
Investigation uncovers forged ethical approval documents
BusinessBattling the US opioid epidemic
Adapt pharma’s naloxone nasal spray makes treating overdoses easier
ResearchChloroform poses new threat to ozone recovery
Models of observational data trace anthropogenic emissions back to China
BusinessBristol-Myers Squibb to buy Celgene for $74 billion
Deal boosts BMS’s cancer and immunology pipeline with 5 drugs in late stage clinical trials
BusinessGSK and Pfizer joint venture creates new consumer healthcare giant
Enlarged GSK consumer health will have largest market share of any firm and be a leader in key countries
ResearchFoam catalyst performs hydrogen evolution in neutral conditions
Structure decouples water dissociation and hydrogen evolution processes
NewsFears of regulatory backlash in wake of gene-edited babies scandal
Chinese scientist behind birth of twins with edited DNA shows little remorse for his actions
BusinessBreaking the silence of RNA interference drugs
A wave of treatments is set to follow the first approval of an RNAi therapy